Section 1: Ad Copy	
Eyebrow	The first FDA-approved treatment indicated for adults with tardive dyskinesia (TD)[1]
Logo	INGREZZA logo
Image/look and feel	Campaign imagery
Headline	**One capsule, once daily**[1]
Subhead	Convenient once-daily dosing without complex titration[1]
Image	Patient image
Image disclaimer	Not an actual patient
Image	40 and 80 mg capsule imagery
Image disclaimer	Not actual size
Copy	• INGREZZA 80 mg provided rapid and significant reductions in TD severity by 6 weeks[1,2] ○ with continued reductions in TD severity through 48 weeks[1,3] • Generally well tolerated in clinical trials across a broad range of TD patients[1,2] • Selectively inhibits VMAT2, with no appreciable binding affinity for dopaminergic (including D2) or serotonergic receptors[1] VMAT2, vesicular monoamine transporter 2.
CTA/booth teaser	**Test your diagnostic skills: is it tardive dyskinesia (TD) or acute extrapyramidal symptoms?**
CTA/booth teaser	**Visit us at booth #TBD**
Bottom band	www.INGREZZAHCP.com

Section 2: Important Safety Information	
H2	Important Safety Information
Copy	**Important Information** **INDICATION & USAGE** INGREZZA® (valbenazine) capsules is indicated for the treatment of adults with tardive dyskinesia.

	IMPORTANT SAFETY INFORMATION **WARNINGS & PRECAUTIONS** **Somnolence** INGREZZA can cause somnolence. Patients should not perform activities requiring mental alertness such as operating a motor vehicle or operating hazardous machinery until they know how they will be affected by INGREZZA. **QT Prolongation** INGREZZA may prolong the QT interval, although the degree of QT prolongation is not clinically significant at concentrations expected with recommended dosing. INGREZZA should be avoided in patients with congenital long QT syndrome or with arrhythmias associated with a prolonged QT interval. For patients at increased risk of a prolonged QT interval, assess the QT interval before increasing the dosage. **ADVERSE REACTIONS** The most common adverse reaction (≥5% and twice the rate of placebo) is somnolence. Other adverse reactions (≥2% and >placebo) include: anticholinergic effects, balance disorders/falls, headache, akathisia, vomiting, nausea, and arthralgia. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit MedWatch at www.fda.gov/medwatch or call 1-800-FDA-1088. **Please see the adjacent page for brief summary of Prescribing Information and visit www.INGREZZAHCP.com for full Prescribing Information.**

References	**REFERENCES: 1.** INGREZZA [package insert]. San Diego, CA: Neurocrine Biosciences, Inc; 2017. **2.** Hauser RA, Factor SA, Marder SR, et al. KINECT 3: a phase 3 randomized, double-blind, placebo-controlled trial of valbenazine for tardive dyskinesia. *Am J Psychiatry*. 2017;174(5):476-484. **3.** Factor SA, Remington G, Comella CL, et al. The effects of valbenazine in participants with tardive dyskinesia: results of the 1-Year KINECT 3 extension study. *J Clin Psychiatry*. 2017;78(9):1344-1350.

Section 3: Copyright info	
Logo	Neurocrine logo
Sign off	
